Wednesday, July 8, 2026

pharma · hidradenitis suppurativa (HS) · Hidradenitis Suppurativa · MLTX

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (NASDAQ: is a pharma organization headquartered in Zug, CH. It trades on NYSE under ticker MLTX. Primary therapeutic focus areas include hidradenitis suppurativa (HS), Hidradenitis Suppurativa

Dorfstrasse, 29, Zug 6300, CH HQ
2021 Founded
133 Employees
Public company Type
MLTX · NYSE Ticker
Company details
Status
Public
HQ
Dorfstrasse, 29, Zug 6300, CH
Founded
2021
Employees
133
Programs
13
Drugs
11
Patents
0

Quick answer

MoonLake Immunotherapeutics (NASDAQ: is a pharma organization headquartered in Zug, CH. It trades on NYSE under ticker MLTX. Primary therapeutic focus areas include hidradenitis suppurativa (HS), Hidradenitis Suppurativa, axial spondyloarthritis, psoriatic arthritis, Hidradenitis suppurativa (HS). NovaPharmaNews links 13 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (8), phase 2 (4), phase 1 (1).

Company snapshot

MoonLake Immunotherapeutics AG is a clinical-stage biopharmaceutical company leveraging revolutionary Nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

  • 13 active pipeline program(s) linked via ClinicalTrials.gov.
  • 13 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for MoonLake Immunotherapeutics. Not investment advice.

Lead pipeline drugs

Active clinical programs

Momentum

Proprietary activity score for MoonLake Immunotherapeutics.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 10 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Recent activity

Latest pipeline, patent, and corporate events for MoonLake Immunotherapeutics.

  1. Clinical update

    M1095-PSA-302 — Phase 3

  2. Clinical update

    M1095-PSA-301 — Phase 3

  3. Clinical update

    M1095-HS-302 — Phase 3

  4. Clinical update

    M1095-HS-301 — Phase 3

  5. Clinical update

    68Ga-FAPI-46, Sonelokimab — Phase 2

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is MoonLake Immunotherapeutics?

    MoonLake Immunotherapeutics (NASDAQ: is a pharma organization headquartered in Zug, CH. It trades on NYSE under ticker MLTX. Primary therapeutic focus areas include hidradenitis suppurativa (HS), Hidradenitis Suppurativa, axial spondyloarthritis, psoriatic arthritis, Hidradenitis

  • Is MoonLake Immunotherapeutics publicly traded?

    Yes. MoonLake Immunotherapeutics is listed with ticker MLTX on NYSE per SEC EDGAR records linked on this profile.

  • What drugs does MoonLake Immunotherapeutics develop or market?

    We link 11 drug profile(s) where MoonLake Immunotherapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/moonlake-immunotherapeutics#company-drugs.

  • What are the latest developments for MoonLake Immunotherapeutics?

    In the last 12 months our linked public records show 13 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does MoonLake Immunotherapeutics focus on?

    MoonLake Immunotherapeutics focuses on hidradenitis suppurativa (HS), Hidradenitis Suppurativa, axial spondyloarthritis based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
26